EGFR and non-small cell lung carcinoma: They investigated the underlying mechanism for the adverse impact of a germline mutation on the survival of the patients who received EGFR tyrosine kinase inhibitors.[15] It provided new insights into the relationship between m6A modification and NSCLC patients’ survival, highlighting the need for a comprehensive assessment of the role of genetic variants in m6A pathway genes and their impact on the survival modulation of NSCLC patients.